Equity Overview
Price & Market Data
Price: $2.19
Daily Change: +$0.07 / 3.20%
Range: $2.09 - $2.19
Market Cap: $293,157,824
Volume: 1,551
Performance Metrics
1 Week: 24.71%
1 Month: -2.08%
3 Months: -31.61%
6 Months: 14.59%
1 Year: 42.28%
YTD: 46.21%
Company Details
Employees: 35
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.